| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2010 | EP2155715A1 ((phenyl)imidazolyl)methylheteroaryl compounds |
| 02/24/2010 | EP2155714A2 Substituted aromatic heterocyclic compounds as fungicides |
| 02/24/2010 | EP2155712A1 3-(imidazolyl)-pyrazoloý3,4-b¨pyridines |
| 02/24/2010 | EP2155711A1 Substituted benzoylamino-indan-2-carboxylic acids and related compounds |
| 02/24/2010 | EP2155707A1 Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| 02/24/2010 | EP2155705A2 Compositions for regulating or modulating quorum sensing in bacteria, methods of using the compounds, and methods of regulating or modulating quorum sensing in bacteria |
| 02/24/2010 | EP2155704A1 Thiadiazole derivatives as antidiabetic agents |
| 02/24/2010 | EP2155700A1 Beta-keto-amide derivatives useful as ion channel modulators |
| 02/24/2010 | EP2155698A1 Novel thermodynamically stable polymorphic form-l of letrozole |
| 02/24/2010 | EP2155697A1 Substituted piperazines |
| 02/24/2010 | EP2155696A2 Piperazine salts as d3/d2 antagonists |
| 02/24/2010 | EP2155695A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| 02/24/2010 | EP2155693A1 Novel 4-phenyl-imidazole-2-thiones used as tyrosinase inhibitors, method for preparing same and use thereof in human medicine and cosmetology |
| 02/24/2010 | EP2155692A1 Non-nucleoside reverse transcriptase inhibitors |
| 02/24/2010 | EP2155690A1 Indazolamide derivatives |
| 02/24/2010 | EP2155689A2 Ccr2 receptor antagonists and uses thereof |
| 02/24/2010 | EP2155687A1 Diacylglycerol acyltransferase inhibitors |
| 02/24/2010 | EP2155683A2 Pyridone derivatives as p38a mapk inhibitors |
| 02/24/2010 | EP2155682A2 Salts of isophosphoramide mustard and analogs thereof |
| 02/24/2010 | EP2155681A1 Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| 02/24/2010 | EP2155680A1 Indanone derivatives that inhibit prolyl hydroxylase |
| 02/24/2010 | EP2155678A1 New bradykinin b1 antagonists |
| 02/24/2010 | EP2155677A1 Mono-hydrochloric salts of an inhibitor of histone deacetylase |
| 02/24/2010 | EP2155676A2 Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| 02/24/2010 | EP2155675A1 Kinase inhibitors, compositions thereof, and methods of use therewith |
| 02/24/2010 | EP2155674A1 Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
| 02/24/2010 | EP2155672A1 Prolinamide derivatives as nk3 antagonists |
| 02/24/2010 | EP2155671A2 New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| 02/24/2010 | EP2155670A1 Anti -inflammatory substituted cyclobutenedione compounds |
| 02/24/2010 | EP2155669A1 New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| 02/24/2010 | EP2155668A2 Crystalline forms of (r)-1-{2-ý4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| 02/24/2010 | EP2155666A1 Azetidine derivatives and their use as prostaglandin e2 antagonists |
| 02/24/2010 | EP2155663A1 Substituted 2- ý2- (phenyl) ethylamino¨alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
| 02/24/2010 | EP2155659A1 Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity |
| 02/24/2010 | EP2155643A1 Ire-1a inhibitors |
| 02/24/2010 | EP2155334A2 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
| 02/24/2010 | EP2155261A1 Sensory feedback-based method for determining the bioavailability of orally administered dietary supplements |
| 02/24/2010 | EP2155252A1 Injectable polymer-lipid blend for localized drug delivery |
| 02/24/2010 | EP2155235A1 Oxygen-generating compositions for enhancing cell and tissue survival in vivo |
| 02/24/2010 | EP2155231A1 Imaging and therapy of virus-associated tumors |
| 02/24/2010 | EP2155230A1 Methods and compositions for use of cyclic analogues of histatin |
| 02/24/2010 | EP2155229A2 Composition for transmucosal delivery of polypeptides |
| 02/24/2010 | EP2155226A2 Compounds for inhibiting protein aggregation, and methods for making and using them |
| 02/24/2010 | EP2155210A2 Use of nucleoside derivatives as anti-koi herpes virus in fish |
| 02/24/2010 | EP2155209A1 Dna polymerase inhibitors composition and methods |
| 02/24/2010 | EP2155208A1 Disaccharides for the treatment of tendons, ligaments and bones |
| 02/24/2010 | EP2155207A2 N-acetyl mannosamine as a therapeutic agent |
| 02/24/2010 | EP2155206A1 Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide |
| 02/24/2010 | EP2155205A1 Treatment of meconium aspiration syndrome with estrogens |
| 02/24/2010 | EP2155204A1 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| 02/24/2010 | EP2155202A2 3,6-disubstituted-imidazo[1,2-b]pyridazines and 3,5-disubstituted pyrazolo[1,5-a]pyrimidines as phosphatidylinositol-3-kinase inhibitors |
| 02/24/2010 | EP2155200A1 Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives |
| 02/24/2010 | EP2155198A2 Piperidine/piperazine derivatives |
| 02/24/2010 | EP2155197A2 Treatment of lysosomal storage diseases |
| 02/24/2010 | EP2155196A1 Methods and compositions for stimulating cells |
| 02/24/2010 | EP2155194A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/24/2010 | EP2155193A1 Use of hdac inhibitors for the treatment of melanoma |
| 02/24/2010 | EP2155192A2 Tetrahydroisoquinolines as tumour growth inhibitors |
| 02/24/2010 | EP2155191A1 Transglutaminase inhibitor comprising egcg and a method for producing thereof |
| 02/24/2010 | EP2155189A2 Direct dissolution of docetaxel in a solvent in polysorbate 80 |
| 02/24/2010 | EP2155187A1 Method of treatment using fused aromatic compounds having anti-diabetic activity |
| 02/24/2010 | EP2155185A1 Detecting succinylacetone |
| 02/24/2010 | EP2155184A2 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 02/24/2010 | EP2155183A1 Amino acid derivatives as calcium channel blockers |
| 02/24/2010 | EP2155181A1 5-htp combination therapy |
| 02/24/2010 | EP2155179A1 Axomadol for treating pain from arthritis |
| 02/24/2010 | EP2155178A1 Spiro compounds for treatment of inflammatory disorders |
| 02/24/2010 | EP2155168A2 Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof |
| 02/24/2010 | EP2155163A1 Composition for injection including propofol and method of preparing the same |
| 02/24/2010 | EP2155162A1 Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same |
| 02/24/2010 | EP2155159A2 Robust rapid disintegration tablet formulation |
| 02/24/2010 | EP2155154A2 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
| 02/24/2010 | EP2155146A1 Methods and compositions for treating skin conditions |
| 02/24/2010 | EP2155139A2 Pack of medicinal tablets |
| 02/24/2010 | EP2155000A1 Particulate-soluble glucan preparation |
| 02/24/2010 | EP2154992A2 Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition |
| 02/24/2010 | EP2154971A2 A synergistic pharmaceutical combination for the treatment of cancer |
| 02/24/2010 | EP2154970A1 Di-substituted amides for enhancing glutamatergic synaptic responses |
| 02/24/2010 | EP2154967A1 Pyrimidine derivatives |
| 02/24/2010 | EP2154966A1 Benzimidazoles and pharmaceutical compositions thereof |
| 02/24/2010 | EP2154965A1 Naphthyridine, derivatives as p13 kinase inhibitors |
| 02/24/2010 | EP2154963A1 Iminopyrrolidone thiol amino acid conjugates, pharmaceutical compositions and methods for the treatment of cancer |
| 02/24/2010 | EP2059520B1 1,4,5,6,7,8-hexahydro-i,2,5-triaza-azulene derivatives as orexin receptor antagonists |
| 02/24/2010 | EP2029596B1 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same |
| 02/24/2010 | EP1981880B1 Use of 4-imidazole derivatives for cns disorders |
| 02/24/2010 | EP1954697B1 Peri condensed tricyclic compounds useful as antibacterial agents |
| 02/24/2010 | EP1931335B1 Hexahydro cyclooctyl pyrazole cannabinoid modulators |
| 02/24/2010 | EP1901750B1 Tumor treatment with gliotoxin derivatives |
| 02/24/2010 | EP1869185B1 Conjugate comprising p21 protein for the treatment of cancer |
| 02/24/2010 | EP1863488B1 Use of amino-substituted 8-n-benzimidazoles |
| 02/24/2010 | EP1808432B1 Amorphous form of cinnamide compound |
| 02/24/2010 | EP1789057B1 Neuroprotective effect of solubilized udca in focal ischemic model |
| 02/24/2010 | EP1748995B1 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both |
| 02/24/2010 | EP1742935B1 Polycyclic pyrazines as potassium ion channel modulators |
| 02/24/2010 | EP1742608B1 Biaromatic compounds which activate ppar(gamma) type receptors, their process of preparation and their use in cosmetic or pharmaceutical compositions |
| 02/24/2010 | EP1729775B1 Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin |
| 02/24/2010 | EP1725267B1 Enzyme-prodrug therapy for prosthetic joint repair |
| 02/24/2010 | EP1701956B1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/24/2010 | EP1689381B1 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases (smc proliferation) |
| 02/24/2010 | EP1658066B9 Adamantylglycine- based inhibitors of dipeptidyl peptidase iv for the treatment of diabetes |